There are multiple tissue sources for MSC's Bone Marrow, Adipose(Fat), Umbilical Cord etc
Beyond our Remestemcel product we have licenced our patents to Tigenix / Takeda for their Alofisel / CX601 cell line which is derived from Adipose tissue. These are being used in the Spanish 100 Patient Covid-19 trial. If that is successful and gets commercialised we will get revenues from that stream as well.
I read a paper last week that was testing BM derived MSC's from Hip Replacement donors (simply because it was readily available and the donors were happy to consent). Surprisingly they seemed in to be equivalent in efficacy to young, healthy donor derived cells...
- Forums
- ASX - By Stock
- MSB
- Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-807
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.14 |
Change
0.035(3.17%) |
Mkt cap ! $1.295B |
Open | High | Low | Value | Volume |
$1.08 | $1.15 | $1.08 | $3.273M | 2.947M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
30 | 84657 | $1.14 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.15 | 348724 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
30 | 83157 | 1.140 |
22 | 103987 | 1.135 |
17 | 116601 | 1.130 |
15 | 217145 | 1.125 |
12 | 145722 | 1.120 |
Price($) | Vol. | No. |
---|---|---|
1.145 | 348692 | 20 |
1.150 | 223042 | 23 |
1.155 | 97847 | 12 |
1.160 | 34360 | 7 |
1.165 | 17418 | 1 |
Last trade - 15.17pm 19/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |